Position in VERA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,343,229
-$1,144,108 QoQ
Shares Held
54,608
-37.0% QoQ
Ownership
0.076%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#89
of 217 holders
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 91%
Shared 0%
None 9%
Common Shares in VERA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Trexquant Investment LP holds $587,455,425 across 144 Biotechnology names. VERA ranks #73 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
505,160 | $35,376,354 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
41,839 | $26,088,290 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
120,122 | $22,496,448 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
83,679 | $20,482,108 | |
| 5 | RARE |
Ultragenyx Pharmaceutical Inc.
|
556,385 | $18,577,695 | |
| 6 | INSM |
INSMED Inc
|
156,553 | $16,691,680 | |
| 7 | SRRK |
Scholar Rock Holding Corp
|
275,712 | $15,164,160 | |
| 8 | EXEL |
Exelixis, Inc.
|
275,209 | $14,974,121 |
All Filings in VERA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,343,229 | 54,608 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,487,337 | 86,685 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,534,785 | 50,055 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $6,059,010 | 208,500 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,603,714 | 152,959 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $1,507,903 | 62,777 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $924,628 | 21,864 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $2,291,283 | 51,839 | Shares | Sole | 2024-11-12 | |
| 2024-03-31 | $499,114 | 11,575 | Shares | Sole | 2024-05-14 | |
| 2023-06-30 | $858,257 | 53,474 | Shares | Sole | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||